Experimental Hematology 31 (2003)
|
|
- Violet Reed
- 5 years ago
- Views:
Transcription
1 Experimental Hematology 31 (2003) Busulfan-cyclophosphamide versus total body irradiation cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned? Christèle Ferry and Gérard Socié Service d Hématologie Greffe de Moelle, Hôpital Saint-Louis, Paris, France Most of the preparative regimens before allogeneic bone marrow transplantation include cyclophosphamide (Cy) with either busulfan (Bu) or total body irradiation (TBI). The Bu-Cy regimen has shown an advantage in chronic myeloid leukemia and TBI-Cy remains the standard conditioning regimen in acute lymphoblastic leukemia, but results are more conflicting in acute myeloid leukemia (AML). We report here the results of the most important studies comparing these two preparative regimens in AML. Survival is superior in all studies for patients treated with TBI and reached statistical significance in one of four trials. Two of three trials show significantly reduced transplant mortality and leukemia relapse. Higher incidences of veno-occlusive disease and hemorrhagic cystitis are reported with Bu. However, our long-term follow-up is limited, and to date no definitive conclusion can be drawn regarding late side effects. New approaches aiming at minimizing the toxicity without impairing the efficacy, such as targeted Bu plasma levels and nonmyeloablative conditioning regimens, seem promising but need to be evaluated further in future prospective studies International Society for Experimental Hematology. Published by Elsevier Inc. Bone marrow transplantation (BMT) is a well-established treatment for leukemia. The antileukemic activity of allogeneic BMT is provided both by the high dose intensity of the preparative regimen and by the immune mediated graftvs-leukemia reaction. Historically, combination of cyclophosphamide (Cy; 120 mg/kg) and total body irradiation (TBI) was the most used conditioning regimen [1,2]. In the 1980s, a radiation-free conditioning the use of Cy (200 mg/ kg) associated with busulfan (Bu) was reported [3,4]. In 1987, Tutschka et al. [5] developed a new conditioning with a reduce dose of Cy (120 mg/kg) to minimize the toxicity without compromising efficacy. Bu offered the advantage of an easier administration than TBI, particularly in small children. Moreover, it possibly could prevent the potential toxic effects of TBI, such as secondary malignancies, interstitial pneumonitis, cataract, growth retardation, and other endocrinologic disturbances. On the other hand, TBI has some advantages. It can eradicate leukemic cells in sanctuary sites such as the central nervous system or the testicles. Problems of drug excretion or metabolism do not exist with Offprint requests to: Gérard Socié, M.D., Ph.D., Service d Hématologie Greffe de Moelle, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France; gsocie@chu-stlouis.fr TBI, unlike with Bu, which has some toxic effects that are rare with TBI, such as veno-occlusive disease of the liver (VOD), hemorrhagic cystitis, and permanent alopecia. Several prospective and retrospective studies were aimed at comparing TBI and Bu associated with Cy as a preparative regimen before allogeneic BMT for acute and chronic leukemia. In chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), results are concordant. In CML, similar or better results after Bu-based regimen were found [6 9]. In ALL, TBI remains the standard regimen, with lower relapse rates, better event-free survival (EFS) [10], and lower transplant-related mortality (TRM) [11] compared to Bu-based regimen. In acute myeloid leukemia (AML), results are not so clear. We report here the results of the most important studies. Survival (Table 1) Conflicting results have been reported in terms of survival. In 1992, a randomized trial comparing Bu (16 mg/kg)-cy (120 mg/kg) vs TBI (10 12 grays)-cy (120 mg/kg) as the preparative regimen in 101 patients with AML in first complete remission (CR1) showed better overall survival with the TBI-Cy regimen (75% vs 51%, p 0.02) [12] X/03 $ see front matter. Copyright 2003 International Society for Experimental Hematology. Published by Elsevier Inc. doi: /j.exphem
2 C. Ferry and G. Socié/ Experimental Hematology 31 (2003) Table 1. Overall survival, leukemia-free survival, toxicity-related mortality, and relapse after Bu-Cy vs TBI-Cy Reference OS LFS TRM Relapse Blaise et al. [12] 51% vs 75% 49% vs 73% 27% vs 8% 34% vs 14% Ringden et al. [15] 54% vs 63% (7 years) 59% vs 56% (7 years) 34% vs 14% 29% vs 29% (7 years) Socie et al. [17] 51% vs 63% (10 years) 47% vs 57% (p = 0.051) Litzow et al. [18] 55% vs 60% (5 years) 54% vs 58% (5 years) 27% vs 30% (5 years) 19% vs 12% (5 years) LFS leukemia-free survival; OS overall survival; TRM treatment-related mortality. This difference was explained by a higher TRM (27% vs 8%, p 0.06) and a higher relapse rate (34% vs 14%, p 0.04) in the Bu-Cy group. The long-term follow-up (median 10.8 years) reported in 2001 [13] confirmed the worst outcome in Bu-based regimen. The 10-year overall survival and leukemia-free survival (LFS) were 59% and 55% in the TBI group vs 43% and 35% in the Bu group, respectively (p 0.04 and p 0.02). In 1994, the Nordic Bone Marrow Transplantation group reported a randomized trial comparing Bu vs TBI in allogeneic transplantation for leukemia [14]. This study initially also found better results in patients receiving TBI. The 3- year overall survival was 76% in the TBI-treated group vs 62% in the Bu-treated group (p 0.03). Relapse-free survival was similar in the two groups. but TRM was higher in the Bu-treated group (28% vs 9%, p 0.006). For patients with advanced disease, LFS was significantly better in the TBI group (p 0.005). However, no separate analysis for patients with AML was provided in this study. In 1999, the same group reported the long-term results of this study [15]. No difference was found with regard to survival. The 7-year overall survival was 54% in the Bu group vs 63% in the TBI group, with no separate analysis with AML. The 7-year LFS also was similar in the Bu vs TBI group (59% vs 56%) in patients with AML. The 7-year cumulative incidence was the same in the two groups (29%). However, results were better with the TBI-based regimen in patients in high-risk groups, with no separate analysis for AML patients. The 7- year LFS was 17% in the Bu group vs 49% in the TBI group (p 0.01), and the 7-year TRM 64% vs 22% (p 0.004). In contrast, a retrospective study comparing Bu and TBI as the preparative regimen for autograft or allograft in acute leukemia found no difference between the two conditioning regimens [16]. Disease-free survival, TRM, and relapse were not significantly different. Four randomized studies have compared these two regimens [6,7,12,14]. The long-term outcome of 316 patients with CML and 172 patients with AML was analyzed [17]. Mean follow-up was more than 7 years. No significant difference in the 10-year overall survival (51% in Bu-treated patients vs 63% in TBI-treated patients) and LFS (47% vs 57%) was observed in patients with AML. A large IBMTR retrospective study compared outcome following allogeneic BMT with Bu-Cy vs TBI-Cy for AML in CR1 [18]. Overall survival, disease-free survival, and TRM were not significantly different in the two groups. Nevertheless, relapse was higher in the Bu group (19% vs 12%, p 0.042), particularly extramedullary relapse (14% vs 10%) and relapse in the central nervous system (3% vs 0%, p 0.016). This study suggested that TBI could be more effective in eradicating leukemic cells at these sites. These results suggest that TBI-Cy regimen is superior to BU-Cy regimen. This also is the conclusion of a metaanalysis of five prospective, randomized, controlled trials comparing the use of Bu-Cy vs TBI-Cy regimen for allogeneic BMT in patients with acute or chronic leukemia [19]. Only one of the five studies compared patients with AML only. Moreover, all of these studies only analyzed the impact of the preparative regimen. Factors known to influence the outcome, such as cytogenetics, number of cells infused, and graft origin, were not included in the different analysis. Toxicity (Table 2) Toxicity of the preparative regimen is a major limiting factor in BMT. Regimens using only chemotherapy, instead of Table 2. Early toxicity of Bu-Cy vs. TBI-Cy Reference Veno-occlusive disease Interstital pneumonia Hemorragic cystitis GVHD II IV Blaise et al. [12] 12% vs 4% 4% vs 10% 31% vs 31% Ringden et al. [14,15] 12% vs 1% 14% vs 10% 24% vs 8% 26% vs 22% Ringden et al. [16] 7% vs 3% 6% vs 12.5% 7% vs 2% 25% vs 31% Socie et al. [17] 6% vs 6% GVHD graft-vs-host disease.
3 1184 C. Ferry and G. Socié/ Experimental Hematology 31 (2003) irradiation-based regimens, have been developed to minimize these toxicities. Nevertheless, early toxicities are an important problem with Bu-containing regimens. In 1991, Morgan et al. [20] compared the toxicity of these two preparative regimens in 233 patients transplanted for acute or chronic leukemia with an HLA-identical sibling donor. Sixty-seven patients received the Bu-Cy preparation and 166 TBI-Cy. VOD and hemorrhagic cystitis appeared to be higher in the Bu-Cy group (19% vs 13%, p ; and 30% vs 14%, p 0.008, respectively). A similar incidence of interstitial pneumonitis was found in the acute leukemia group. Studies comparing the two conditioning regimens in patients with AML showed more early complications with the Bu-based regimen in most of the patients. The French study found no difference in the incidence of interstitial pneumonitis, VOD or hemorrhagic cystitis between the two groups. However, there was a trend toward a higher mortality from a nonleukemic cause in the Bu group (28% vs 8%, p 0.06). The Nordic Bone Marrow Transplant Group [14] found in its randomized trial a significantly higher incidence of TRM in patients both with early and with advanced disease receiving Bu (p 0.002). In the latter group, the difference was 62% for Bu patients vs 12% for TBI patients. The incidence of grade III IV acute graft-vs-host disease (GVHD) also was higher in the Bu group (15% vs 4%, p 0.04), as was the incidence of death related to GVHD (17 vs 2%, p 0.003). The incidences of VOD and hemorrhagic cystitis also were higher in the Bu group (12% vs.1%, p 0.009; and 24% vs 8%, p 0.003; respectively). No difference was found with regard to the incidence of interstitial pneumonitis. In a retrospective study, Ringden et al. [16] found a higher incidence of TRM with Bu in patients with AML in CR1. The incidence of acute GVHD was similar in the two groups. VOD and hemorrhagic cystitis were higher in the Bu group (7% vs 3%, p 0.02; and 7% vs 2%, p , respectively). Interstitial pneumonitis were more frequent in the TBI group (12.5% vs 6%, p 0.008). A more recent study showed a similar incidence of TRM but a higher incidence of VOD in the Bu group (13% vs 6%, p 0.009) [18]. In conclusion, VOD and hemorrhagic cystitis occur more frequently in patients receiving Bu, and no advantage of TRM was found in the Bu-based conditioning regimen. However, none of these studies measured Bu plasma levels. It now is well known that Bu plasma levels are an important factor for toxicity. In 1997, Ljungman et al. [21] demonstrated that high Bu concentrations ( 721 ng/ml) were independently associated with lower overall survival, LFS, and higher TRM. Monitoring of Bu plasma levels leads to a lower incidence of VOD without impairment of the efficacy [22]. Furthermore, as suggested by a reported by Lee et al. [23], the combination of Bu and Cy has a synergistic effect in terms of toxicity. Pharmacokinetics studies have shown that Bu affects the clearance of Cy. Hassan et al. [24] demonstrated that the clearance of Cy is affected by the time between its administration and the last dose of Bu. They found a longer elimination half-life of Cy and an increase of its cytotoxic metabolite if Cy is administered less than 24 hours after the last dose of Bu. The consequences are an increased incidence of VOD and mucositis. Better comprehension of the pharmacokinetics and pharmacodynamics of Bu and Cy is an important step to improving the tolerance and efficacy of this regimen. Future prospective studies are necessary to address these uncertainties. Late side effects (Table 3) If efficacy is one of the most important factors in the choice of preparative regimen, long-term side effects also should be considered. Secondary malignancies are a major concern in long-term survivors after BMT. Curtis et al. [25] evaluated the risk of the development of new solid cancer in 19,229 patients who received allogeneic BMT. In this study, patients receiving a preparative regimen including irradiation had a higher risk of second cancer than those who did not receive radiotherapy. This risk increased with the dose of radiation. A long follow-up is necessary to detect these complications, as the risk of new cancer increases over time. The cumulative incidence rate was 0.7% at 5 years, 2.2% at 10 years, and 6.7% at 15 years. In children, a study of long-term survivors after BMT for childhood leukemia [26] showed that children who received high-dose TBI before transplantation for leukemia were at higher risk for developing solid tumor (relative risk 3.1). In studies comparing Bu-based or TBI-based regimen in patients with AML, the authors did not observe a higher Table 3. Late effects of Bu-Cy vs. TBI-Cy Reference Follow-up Cataracts Alopecia Chronic GVHD Blaise et al. [12] 23 months 38% vs 30% Ringden et al. [15] 87 months 10% vs 31% 28% vs 6% 45% vs 35% Ringden et al. [16] 21% vs 25% Socié et al. [17] 7 years 12.3% vs 12.4% 72% vs 55% 20% vs 19% Litzow et al. [18] 55 months 39% vs 37% GVHD graft-vs-host disease.
4 C. Ferry and G. Socié/ Experimental Hematology 31 (2003) incidence of cancer in the TBI group, but follow-up may not have been sufficiently long (5 10 years) [13,15,17]. However, these studies demonstrated that secondary malignancies also could occur after Bu-based preparative regimen. Nonmalignant late effects are well described [27] and usually multifactorial. The conditioning regimen frequently is involved in the development of these side effects. Endocrinologic disturbances are frequent after TBI, but results are less clear after a Bu-based conditioning regimen. Growth impairment is well established after a TBI-based regimen. Several studies also suggest that the combination of Bu and Cy before BMT can similarly affect growth rates [28,29]. In contrast, other investigators did not find any significant growth impairment after a Bu-based regimen [30 32]. Irradiation is known to induce thyroid dysfunction, but some studies suggest that chemotherapy alone before BMT also can induce thyroid function abnormalities. In 1997, Al Fiar et al. [33] compared thyroid function in 270 adults, based on conditioning regimens. They found almost the same incidence of elevated thyroid stimulating hormone with the Bu-based regimen (11.7%) than with fractionated TBI at 12 grays (16.7%). Similar results were found in children. In a study from the SFGM after allogeneic BMT for AML in first CR1, children treated with TBI experienced a higher incidence of hypothyroidism than those treated with Bu (43% 15% vs 9% 8% at 6 years) [30]. However all patients who developed hypothyroidism after TBI received unfractionated TBI. Gonadal failure is one of the most frequent complications after BMT, whatever the type of preparative regimen [34,35]. After TBI, pregnancies are rare but possible, and the risk of spontaneous abortion is increased [36]. A study reported by Anserini et al. [37] analyzed the semen in 64 men after BMT and showed a trend toward higher spermatogenesis recovery rate after the Bu-Cy compared with the TBI-Cy preparative regimen (p 0.069). Other non life-threatening complications can affect quality of life after BMT. Cataract is a frequent late complication after TBI [38], but it also occurs after irradiation-free regimens. The long-term results of the Nordic BMT group [15] showed a higher incidence of cataracts in the TBI group (31% vs 10%, p 0.002), but most of the patients in the TBI group who developed cataract received TBI in a single session. The long-term follow-up of the four randomized studies comparing Bu and TBI as preparative regimen before transplantation for leukemia found an overall higher incidence of cataracts in the TBI group, but among patients with AML, the 7-year cumulative incidence was not different between the two groups (12.3% in the Bu group vs 12.4% in the TBI group) [17]. Permanent alopecia is a frequent complication affecting quality of life after transplantation. The Nordic BMT group [15] found partial or total alopecia in 37.7% patients after Bu conditioning and partial alopecia in 10.8% patients after TBI. Total alopecia did not occur after TBI. The longterm results of the four randomized studies [17] also showed an increased incidence of alopecia in patients with AML who received Bu-Cy. Chronic GVHD leads to late transplant-related morbidity or mortality. Only the Nordic study [15] found a higher incidence of chronic GVHD in the Bu group (59% vs 47%, p 0.05). They also found that death related to GVHD was more common in the Bu group (22% vs 3%, p 0.001). Others studies did not find any difference in chronic GVHD incidence [13,17,18], but GVHD-related mortality in the French study [13] was higher in the Bu-Cy group (p 0.05). Both regimens are responsible for late complications, and even today it still is difficult to establish which regimen provides the lower toxicity rate. Some complications, such as secondary malignancies, appear late after transplantation; thus, longer follow-up is needed to precisely compare late complications related to the conditioning regimen. Conclusion Cy-TBI appears to be superior to Bu-Cy in terms of survival and LFS in patients with AML, especially in patients with advanced disease. Both TRM and relapse are reduced in patients undergoing TBI. Statistical significance for these differences were reached in some but not all trials. Early toxicity is an important problem with Bu, and higher incidences of VOD and hemorrhagic cystitis are reported. Longterm side effects (alopecia, cataracts, chronic GVHD, second tumors) after a median follow-up of more than 7 years seem to be comparable in the two regimens. Where do we go from here?: patients with AML should receive TBI when available, and Bu should be second-choice regimen. Targeted Bu is a new promising method for administration of Bu, but we do not know how these early encouraging results will compare with conventional TBI-based regimens. Careful monitoring of early and late complications, as well as prospective randomized trials, hopefully will establish optimal conditioning regimens in the rapidly evolving world of allogeneic hematopoietic stem cell transplant for acute leukemia. References 1. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49: Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 1979;301: Santos GW. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant. 1989;4(suppl 1): Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309: Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:
5 1186 C. Ferry and G. Socié/ Experimental Hematology 31 (2003) Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84: Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood. 1995;85: Kim I, Park S, Kim BK, et al. Allogeneic bone marrowtransplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans. Clin Transplant. 2001;15: Kroger N, Zabelina T, Kruger W, et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant. 2001;27: Granados E, de La Camara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term eventfree survival with conditioning regimens containing total body irradiation. Haematologica. 2000;85: Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18: Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d Etudes de la Greffe de Moelle Osseuse. Blood. 1992;79: Blaise D, Maraninchi D, Michallet M, et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood. 2001;97: Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan withtotal body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83: Ringden O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood. 1999;93: Ringden O, Labopin M, Tura S, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996;93: Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98: Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002;119: Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant. 1998;22: Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol. 1991;77: Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1997;20: Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28: Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Venoocclusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999;5: Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25: Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336: Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18: Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101: Wingard JR, Plotnick LP, Freemer CS, et al. Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood. 1992;79: Sanders JE. Endocrine problems in children after bone marrow transplant for hematologic malignancies. The Long-term Follow-up Team. Bone Marrow Transplant. 1991;8(suppl 1): Michel G, Socie G, Gebhard F, et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 1997;15: Giorgiani G, Bozzola M, Locatelli F, et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood. 1995;86: Cohen A, Rovelli A, Bakker B, et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood. 1999;93: Al-Fiar FZ, Colwill R, Lipton JH, Fyles G, Spaner D, Messner H. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants. Bone Marrow Transplant. 1997; 19: Sanders JE. The impact of marrow transplant preparative regimens on subsequent growth and development. The Seattle Marrow Transplant Team. Semin Hematol. 1991;28: Tauchmanova L, Selleri C, Rosa GD, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer. 2002;95: Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87: Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant. 2002;30: Thomas O, Mahe M, Campion L, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys. 2001; 49:
Late complications after hematopoietic stem cell transplant in adult patients
Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More information2/4/14. Disclosure. Learning Objective
Utilizing Intravenous Busulfan Pharmacokinetics for Dosing Busulfan And Fludarabine Conditioning Regimens In Institutions Where The Capability Of Doing Pharmacokinetics Is Not Present Shaily Arora, PharmD
More informationPost-transplant complications Cataracts in patients receiving stem cell transplantation after conditioning with total body irradiation
(2002) 29, 503 507 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Post-transplant complications Cataracts in patients receiving stem cell transplantation after
More informationFeasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
ORIGINAL ARTICLE korean j intern med 212;27:72-83 pissn 1226-333 eissn 25-6648 Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationM Cavo, G Bandini, M Benni, A Gozzetti, S Ronconi, G Rosti, E Zamagni, RM Lemoli, A Bonini, A Belardinelli, MR Motta, S Rizzi and S Tura
Bone Marrow Transplantation, (1998) 22, 27 32 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt High-dose busulfan and cyclophosphamide are an effective conditioning
More informationKEY WORDS Busulfan Fludarabine Thymoglobulin AML ALL Remission
Biology of Blood and Marrow Transplantation 13:814-821 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1307-0001$32.00/0 doi:10.1016/j.bbmt.2007.03.003 Allogeneic Transplantation
More informationLondon, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION
London, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION 1 Introduction Busilvex contains the active substance busulfan in a concentrate for solution for
More informationLate effects, health status and quality of life after hemopoietic stem cell
Late effects, health status and quality of life after hemopoietic stem cell transplantation (HSCT) THE 13th ESH-EBMT TRAINING COURSE ON BLOOD AND MARROW TRANSPLANTATION EBMT Slide template Barcelona 7
More informationMini Review Myeloablative conditioning regimens for AML allografts: 30 years later
(2003) 32, 969 978 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Mini Review Myeloablative conditioning s for AML allografts: 30 years later V Gupta 1, HM Lazarus
More informationLate effects after HSCT
Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationWei Tang, Ling Wang, Wei-Li Zhao, Yu-Bao Chen, Zhi-Xiang Shen, Jiong Hu
Biol Blood Marrow Transplant 17:1546-1568, 2011 i.v. Bu-Cy as a Preparative Regimen Before allo-hsct 1555 Sharma, and Gabriela Rondon assisted with data collection and reviewed and approved the manuscript.
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationOrgan toxicity and quality of life after allogeneic bone marrow transplantation in pediatric patients: a single centre retrospective analysis
Bone Marrow Transplantation, (1999) 23, 1049 1053 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Organ toxicity and quality of life after allogeneic bone
More informationBONE MARROW TRANSPLANTATION FOR HAEMATOLOGICAL DISORDERS DURING
5Chapter 5 FINAL HEIGHT OF PATIENTS WHO UNDERWENT BONE MARROW TRANSPLANTATION FOR HAEMATOLOGICAL DISORDERS DURING CHILDHOOD: A STUDY BY THE WORKING PARTY FOR LATE EFFECTS-EBMT Blood 1999;93:4109-4115 Cohen
More informationoptions in Myeloablative HSCT
Should Busilvex we use AlloSCT in AML options in Myeloablative HSCT Reduced Intensity or Myeloablative preparative protocols? Moderator: Andrea Bacigalupo Reduced Intensity: Arnon Nagler Myeloablative:
More informationAllogenic Stem Cell Transplantation and Total Body Irradiation
TURKISH JOURNAL of ONCOLOGY REVIEW Allogenic Stem Cell Transplantation and Total Body Irradiation Serra KAMER Department of Radiation Oncology, Ege University Faculty of Medicine, İzmir-Turkey SUMMARY
More informationASBMT. Hugo F. Fernandez, 1 Hai T. Tran, 2 Federico Albrecht, 1 Shari Lennon, 3 Humberto Caldera, 1 Mark S. Goodman 1
Biology of Blood and Marrow Transplantation 8:486-492 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Evaluation of Safety and Pharmacokinetics of Administering Intravenous Busulfan
More informationRelapse Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
(2004) 34, 721 727 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $30.00 www.nature.com/bmt Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling
More informationHematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia
398 Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia Qifa Uu Zhiping Fan Jing Sun Yu Zhang Xiaoli Uu Dan Xu Bing Xu Ru Feng Fanyi Meng Shuyun Zhou Department of Hematology,
More informationBusulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate
Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute
More informationBusulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity
Bone Marrow Transplantation, (1997) 19, 1169 1173 1997 Stockton Press All rights reserved 0268 3369/97 $12.00 Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and
More informationAllogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission Je-Hwan Lee 1, Sung-Soo
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationORIGINAL ARTICLE INTRODUCTION THE KOREAN JOURNAL OF HEMATOLOGY
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationHematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0004$32.00/0 doi:10.1016/j.bbmt.2005.06.004 High Disease Burden
More informationKT Godder, J Metha, KY Chiang, S Adams, F van Rhee, S Singhal, K Higgins-Smith, W O Neal, S DeRienzo and JP Henslee-Downey.
(2001) 28, 1031 1036 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Acute myeloid leukaemia Partially mismatched related donor bone marrow transplantation as salvage
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationBMT CLINICAL TRIALS NETWORK RIC vs. MAC Protocol # 0901 Version 5.0 dated March 3, 2014
Core Study Participants: Baylor College of Medicine (Methodist ) BMT at Northside Hospital Case Western Reserve University Consortia Cleveland Clinic Foundation Oregon Health and Science University University
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 24 AUGUST 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationMyelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers
(23) 32, 35 4 & 23 Nature Publishing Group All rights reserved 268-3369/3 $25. www.nature.com/bmt Myelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers A Daly 1,
More informationUse of drug pharmacokinetics in conditioning regimen
Use of drug pharmacokinetics in conditioning regimen Jayr Schmidt Filho, MD A.C.Camargo Cancer Center Oncohematology team UCTC HC-FMUSP/ ICESP Medical Coordinator Disclosures No disclosures for this lecture!
More informationReduced-Intensity Allogeneic Bone Marrow Transplantation
Reduced-Intensity Allogeneic Bone Marrow Transplantation Session Chair: Claudio Anasetti, MD Speakers: Brenda M. Sandmaier, MD; Issa F. Khouri, MD; and Franco Locatelli, MD Outcomes with Myeloid Malignancies
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationOmori et al. SpringerPlus 2013, 2:424 a SpringerOpen Journal
Omori et al. SpringerPlus 2013, 2:424 a SpringerOpen Journal RESEARCH Eleven secondary cancers after hematopoietic stem cell transplantation using a total body irradiation-based regimen in 370 consecutive
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationHaematopoietic stem cell transplantation (SCT)
HAEMATOPOIETIC TEM CELL TRANPLANTATION FOR CHILREN IN BELGIUM Marie-Françoise resse 1 & Yves Beguin 2 1 epartment of Paediatrics, ivision of Hemato-Oncology, UHOPL, University of Liege, Liège, Belgium;
More informationFeasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
The Open Leukemia Journal, 2010, 3, 55-59 55 Open Access Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than Years
More informationAutologous bone marrow transplantation for patients with acute myeloid leukaemia: prospective follow-up study
Bone marrow transplantation Autologous bone marrow transplantation for patients with acute myeloid leukaemia: prospective follow-up study YK Mak, CH Chan, YC Chu, YT Chen, CK Lau, JSM Lau Objective. To
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationLong-Term Outcomes After Hematopoietic Cell Transplantation
Long-Term Outcomes After Hematopoietic Cell Transplantation Conflicts of Interest No relevant financial conflicts of interest Navneet Majhail, MD, MS Medical Director, NMDP Assistant Scientific Director,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/28461 holds various files of this Leiden University dissertation. Author: Brink, Marloes Hendrika ten Title: Individualized therapeutics in allogeneic stem
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationKEY WORDS: Total body irradiation, acute myelogenous leukemia, relapse
The Addition of 400 cgy Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality
More informationEndocrine Late Effects in Survivors of Pediatric SCT
Endocrine Late Effects in Survivors of Pediatric SCT Daphna Hutt Pediatric Hem-Onc & BMT Sheba Medical Center, Israel #EBMT2015 www.ebmt.org Stiller CA (2007). Childhood Cancer In Britain. Oxford University
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationHee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia Hee-Je
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationClinical Use of Umbilical Cord Blood Hematopoietic Stem Cells
Biology of Blood and Marrow Transplantation 12:34-41 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0107$32.00/0 doi:10.1016/j.bbmt.2005.09.006 Clinical Use of Umbilical
More informationRIC in Allogeneic Stem Cell Transplantation
RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/2296
More informationTransition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology
Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent
More informationA CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES
Chinese Journal of Cancer Research 9(1):36--40,1997, Clinical Observations A CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES Liu
More informationXiao-Jun Huang & Yu Wang & Dai-Hong Liu & Lan-Ping Xu & Huan Chen & Yu-Hong Chen & Wei Han & Hong-Xia Shi & Kai-Yan Liu
J Clin Immunol (2008) 28:390 397 DOI 10.1007/s10875-008-9193-4 Modified Donor Lymphocyte Infusion (DLI) for the Prophylaxis of Leukemia Relapse after Hematopoietic Stem Cell Transplantation in Patients
More informationReduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink
Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink Avichi Shimoni, Arnon Nagler Hematology Division and BMT, Chaim Sheba Medical Center,
More informationH Schroeder 1, G Gustafsson 2, UM Saarinen-Pihkala 3, A Glomstein 4, G Jonmundsson 5, K Nysom 6, O Ringdén 7 and L Mellander 8.
Bone Marrow Transplantation, (1999) 23, 555 560 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Allogeneic bone marrow transplantation in second remission
More informationTransplantation with unrelated bone marrow in leukaemic patients above 40 years of age
Bone Marrow Transplantation, (1998) 21, 43 49 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age O Ringdén
More informationMedical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12
Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11,
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationGONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
original paper Haematologica 1994; 79:141-147 GONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA Fiorina Giona*, Luciana Annino*, Paola Donato, Michele
More informationBB&MT. KEY WORDS Acute lymphoblastic leukemia Hematopoietic stem cell transplantation Therapy Adult
Biology of Blood and Marrow Transplantation 12:1-30 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0001$32.00/0 doi:10.1016/j.bbmt.2005.10.018 The Role of Cytotoxic
More informationHemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;
Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationThe effects of cancer treatment on male infertility
The effects of cancer treatment on male infertility Kirsi Jahnukainen Children s Hospital, Helsinki Karolinska Institutet, Stockholm Department of Pediatrics 21.11.2017 1 Disclosure statement I declare
More informationLate effects and long-term survivorship after HSCT
Late effects and long-term survivorship after HSCT André Tichelli What are late effects? Why is it of importance? How to proceed in daily routine? 59-year old male survivor 22 years after allogeneic HSCT
More informationHigh-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 12:703-711 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0002$32.00/0 doi:10.1016/j.bbmt.2006.02.009 High-Dose Carmustine,
More informationLate Effects after Transplantation for Pediatric Severe Aplastic Anemia. Jean E. Sanders, M.D.
Late Effects after Transplantation for Pediatric Severe Aplastic Anemia Jean E. Sanders, M.D. Patient Characteristics Acquired Fanconi Number 137 15 Gender F:M 63:74 9:6 Etiology: Idiopathic Hepatitis
More informationClinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias
Go Clinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias Number: 0640 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Additional Information
More informationKEY WORDS. Acute lymphoblastic leukemia Etoposide Cyclophosphamide Total body irradiation Conditioning regimen Sibling allografts
Biology of Blood and Marrow Transplantation 12:438-453 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1204-0007$32.00/0 doi:10.1016/j.bbmt.2005.12.029 A Comparison of Cyclophosphamide
More informationDoes anti-thymocyte globulin have a place in busulfan/fludarabine
ORIGINAL ARTICLE Korean J Intern Med 2016;31:750-761 Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Young
More informationPediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center
Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology
More informationAllogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia
Chapter 2 / Allogeneic BMT for AML 13 2 Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia Henry C. Fung, MD and Stephen J. Forman, MD CONTENTS INTRODUCTION
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationINTRODUCTION Rabbit antithymocyte globulin (ratg), a polyclonal antibody that targets human T lymphocytes, is
Total and Active Rabbit Antithymocyte Globulin (ratg;thymoglobulinò) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation Sandra K. Call, 1,2 Kimberly A. Kasow,
More informationAutologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic Leukemia: Comparative Toxicity and Outcomes
Biology of Blood and Marrow Transplantation 8:213-220 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Autologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic
More information4100: Cellular Therapy Essential Data Follow-Up Form
4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:
More informationIntensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Bone Marrow Transplantation, (1998) 22, 1029 1033 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 http://www.stockton-press.co.uk/bmt Intensified conditioning regimen in bone marrow transplantation
More informationOptimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS)
Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) H. Joachim Deeg Myelodysplastic syndrome (MDS) is a hemopoietic stem cell disorder that is potentially curable by transplantation
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationNiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute Adult Umbilical Cord Blood Transplantation
More informationProtocol. Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic (80132) Medical Benefit Effective Date: 07/01/14 Next Review Date: 07/18 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 03/10, 03/11,
More informationINTRODUCTION PATIENTS AND METHODS. Pediatr Blood Cancer 2013;60:
Pediatr Blood Cancer 2013;60:1792 1797 Long-Term Follow-Up of Pediatric Patients Receiving Total Body Irradiation Before Hematopoietic Stem Cell Transplantation and Post-Transplant Survival of >2 Years
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More information